secwatch.observer — SEC 8-K summary
======================================

Issuer:     ProMIS Neurosciences Inc. (PMN)
CIK:        0001374339
Form:       8-K
Filed at:   2023-04-10T23:59:59+00:00
Accession:  0001104659-23-043318
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ProMIS Neurosciences submits IND to FDA for Alzheimer's antibody PMN310
-----------------------------------------------------------------------

- IND filed for PMN310, a monoclonal antibody targeting toxic amyloid-beta oligomers in Alzheimer's disease.
- PMN310 designed for high selectivity to toxic oligomers, potentially reducing ARIA risk vs other antibodies.
- Company expects to become a clinical-stage company pending FDA clearance of the IND.
- Preclinical data showed strong ex vivo target engagement and favorable in vitro comparison to other Aβ antibodies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1374339/000110465923043318/0001104659-23-043318-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1374339/000110465923043318/tm2312175d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-043318

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer